## PATENT COOPERATION TREATY

# **PCT**

### INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PCT002SS	FOR FURTHER ACTION	see Notification of Transmit (Form PCT/ISA/220) as wel		
International application No.	International filing de	ate (day/month/year)	(Earliest) Pr	iority Date (day/month/year)
PCT/IN 2003/000400	26 December	2003 (26.12.2003)		
Applicant	1			
ALL INDIA INSTITUTE OF M	MEDICAL SCIE	NCES		
This international search report has be according to Article 18. A copy is being	en prepared by this I	nternational Searching Auth International Bureau.	ority and is t	ransmitted to the applicant
This international search report consis	its of a total of	sheets.		
It is also accompan	nied by a copy of eac	h prior art document cited in	this report.	
Basis of the report     a. With regard to the language language in which it was fill.	the international se led, unless otherwise	arch was carried out on the l indicated under this item.	basis of the in	nternational application in the
Authority (Rule 23.1(b	o)).			nal application furnished to this
b. With regard to any nucleoti search was carried out on th	de and/or amino aci e basis of the sequen	id sequence disclosed in the ace listing:	international	application, the international
contained in the interna	ational application in	written form.		
iled together with the	international applica	tion in computer readable fo	rm.	
furnished subsequently	to this Authority in	written form.		
furnished subsequently	to this Authority in	computer readable form.		
the statement that the s	ubsequently furnishe filed has been furnish	ed written sequence listing de ned.	oes not go be	eyond the disclosure in the
the statement that the i been furnished.	nformation recorded	in computer readable form i	s identical to	the written sequence listing has
2. Certain claims were f	ound unsearchable	(See Box I).		
3. Unity of invention is I	acking (See Box II).			
4. With regard to the title,				
the text is approved as	submitted by the app	plicant.		
the text has been estab	lished by this Author	rity to read as follows:		
5. With regard to the abstract,				
the text is approved as	submitted by the app	plicant.		
the text has been estab within one month from	lished, according to nother date of mailing	Rule 38.2(b), by this Author of this international search r	ity as it appe eport, submi	ars in Box III. The applicant may, t comments to this Authority.
6. The figure of the drawings to be	published with the	abstract is Figure No.:	-	
as suggested by the ap	plicant.		$\boxtimes$	None of the figures.
because the applicant	failed to suggest a fig	gure.		
because this figure bet	ter characterizes the	invention.		

Form PCT/ISA/210 (first sheet) (July 1998)

International application No. PCT/IN 2003/000400

# CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 14/44, C12Q 1/68, G01N 33/569

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

## IPC7: C07K, C12Q, G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

# WPI, EPODOC, Pubmed, Swiss-Prot, Entrez Protein, Entrez Nucleotide

Category	CUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 1994 016331 (Jasys Corporation) 21 July 1994 (21.07.1994) the whole document	1-36
A	Burns JM Jr, et al. "Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis." Proc Natl Acad Sci U S A. 1993, Vol. 90, No. 2, Pages 775-9. the whole document	1-36
A	Kumar R, et al. "Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis." Clin Diagn Lab Immunol. 2001, Vol. 8, No. 6, Pages 1220-4. the whole document	1-36

Further documents are listed in the continuation of Box C.	See patent family annex.
<ul> <li>Special categories of cited documents:         <ul> <li>A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>E" carlier application or patent but published on or after the international filing date</li> <li>L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>O" document referring to an oral disclosure, use, exhibition or other means</li> <li>P" document published prior to the international filing date but later than</li> </ul> </li> </ul>	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same putent family
the priority date claimed  Date of the actual completion of the international search	Date of mailing of the international search report
27 August 2004 (27.08.2004)	3 September 2004 (03.09.2004)
Name and mailing adress of the ISA/AT Austrian Patent Office Dresdner Straße 87, A-1200 Vienna	Authorized officer  GÖRNER W.  Telephone No. 1/53424/558
Facsimile No. 1/53424/535	

Form PCT/ISA/210 (second sheet) (July 1998)

International application No.

PCT/IN 2003/000400

C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Α	Singh S, et al. "Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis." J Parasitol. 1995, Vol. 81, No. 6, Pages 1000-3. the whole document	1-36
Α	Braz RF, et al. "The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection." Am J Trop Med Hyg. 2002, Vol. 67, No. 4, Pages 344-8. the whole document	1-36
Α	Singh S, et al. "Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen." Clin Diagn Lab Immunol. 2002, Vol. 9, No. 3, Pages 568-72. the whole document	1-36
A	Badaro R, et al. "rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis." J Infect Dis. 1996, Vol. 173, No. 3, Pages 758-61. the whole document	1-36
A	Qu JQ, et al. "Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin." Trans R Soc Trop Med Hyg. 1994, Vol. 88, No. 5, Pages 543-5. the whole document	1-36

Information on patent family members

International application No.
PCT/IN 03/00400-0

Patent document cited in search report	Publication date	Palent family member(s)	Publication date
A		none	
		•	

International application No. PCT/IN 2003/000400

### Supplemental sheet

### Restrictions of the search

- -Claim 1 refers to a polypetide, "wherein said polypeptide contains one or more repeat region(s) of 39 amino acids". Due to this broad and vague definition, only sequences according to Seq ID 5 and Seq ID 6 were included in the search.
- Claim 3 refers to "the polypeptides as claimed in claim 1, isolated from Indian strains of Leishmania donovani". Due to this broad and vague definition, only the strains disclosed in the application were included in the search, namely strains MHOM/IN/DD8 and MHOM/IN/KE16/1998.
- -The "diagnostic kit for detecting leishmanial antigen comprising antibody bound to a solid support" as claimed in Claim 32 does not define the nature of the antibody used and was therefore restricted to antibodies according to claim 22 and a method according to claim 24.

Form PCT/ISA/210 (extra sheet) (July 1998)